Lightsense Technology offering is now closed and is no longer accepting investments.

Public Health Detection Simplified

INVEST IN LIGHTSENSE TECHNOLOGY TODAY!

At Lightsense, we use optics, along with machine learning and analysis to provide better solutions for critical areas of public health like food safety, the overuse of antibiotics, and the opioid crisis. That’s why we developed a revolutionary new multispectral technology platform to redefine spectroscopy - providing a new generation of spectroscopic tools for analyzing materials and biological systems. Our company is pre-revenue and in prototyping stages with multiple patents and partnership paths underway.
... Show more
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Lightsense Technology

Reasons to Invest

  • We provide unique solutions to intractable problems in public health.
  • Our unique EPS technology is applicable to many important and growing markets.
  • Lightsense has a strong and experienced management team with innovative differentiated products powering future SaaS and disposable revenue pathways.




OVERVIEW


At Lightsense, we’re breaking new ground in public health

That’s because we are translating expensive, tabletop spectrometer instrumentation into miniaturized, handheld platforms - all with AI/ML powered optical detection technology that can serve a wide range of analytical applications.



Our focus is on utilizing this new class of tools to help solve some major problems in public health - such as detecting fentanyl and other illicit drugs in the opioid epidemic, detecting viral pathogens in the COVID-19 pandemic, as well as detecting bacterial pathogens in the food safety field.



We are a diverse and experienced group of successful scientists, engineers, and entrepreneurs focused on using modern optics techniques (especially miniaturized spectroscopy), advances in sensors and machine learning to attack problems related to public health in new, insightful ways.



THE PROBLEM


Public Health is facing some critical problems


In all the critical areas of public health - the common thread is that detection and testing solutions need to be faster, less expensive and more accurate. 


THE SOLUTION


Meet the Multispectral Point-of-Need Analyzers

Lightsense has developed a multi-spectral technology platform, the patented “Enhanced Photodetection Spectroscopy” (EPS) , a radical new spectroscopy architecture, for chemical, molecular and pathogen identification. 

 

Our devices can address critical analytical and detection problems in multiple areas of public health -  like rapid detection of illicit drugs, rapid screening for viral/bacterial pathogens, and monitoring bacterial pathogens in various parts of the food supply chain.




When it comes to the science: Spectroscopy uses light of many wavelengths to analyze objects or chemical compounds. This light energy interrogates the molecule of interest and produces a spectral response - creating what scientists call a “spectral fingerprint.” This fingerprint contains large amounts of data, and with our multispectral approach, data fusion and analysis, we can increase sensitivity. AI/ML can be used to detect known patterns and monitor samples, like in the three mentioned areas of public health, above, where we are creating solutions and partnerships.  




Machine Learning is a critical feature in our technology. It not only uses algorithms to detect patterns otherwise not visible and predict outcomes, EPS spectra contain large amounts of data which are aggregated in Cloud databases, allowing monetizing them as a new subscription service. 



Our business model includes both hardware and SaaS components. What makes us unique is a radical new and patented spectroscopy that integrates three or more individual spectroscopies with data fusion and machine learning analytics. Our miniaturization technology allows the construction of integrated small and handheld instruments. 

 

Our IP can also be licensed along with products in specific domain applications. Unique solutions can be crafted for individual partners and customers justifying licensing agreements and related higher margins.


We project our various hardware platforms to cost between $5K and $20K, and we believe we can outperform more expensive competing products, both in performance and in simplicity and ease of use. We project additional revenue from software (SaaS subscriptions) and for certain applications, disposable sample holders. 







THE MARKET


Applications in a Multitude of Industries 

Our applications and technology will find applications beyond traditional areas of Public Health. We anticipate that our devices will address critical analytical and detection problems in a wide range of large vertical markets.

 

Here’s the Total Addressable Markets (TAMS) from our initial focus markets. 




Lightsense miniaturized handheld spectrometers can be used in a variety of analysis applications with performance comparable to that of laboratory instruments, but at a dramatically lower cost, and ease of use. 


Our handheld spectrometers, both current products and instruments under development, are lightweight, easy to use, accurate, faster, and less expensive than competing technologies. We believe our technology will reach a multitude of industries.

Our Traction


Completed first raise, and accelerating with a second

We completed our first seed “A1” raise with SeedInvest, and will accelerate our developments with a second “A2” seed round now. 


Among our recent accomplishments, we received a Food and Beverage Magazine Award for the top 10 food safety solutions providers (Source).

 

The basis for the Lightsense technology portfolio has been developed by a seasoned and accomplished team over many years. Collectively, we’ve been granted over 150 patents in our careers, on a wide range of technologies.  


Currently, the Lightsense patent portfolio lineup includes:

  • 7 issued or allowed patents on miniaturized spectrometers and EPS multi-spectral designs, including both Lightsense owned and exclusively licensed
  • 4 patent applications
  • Multiple patent applications in preparation


WHY INVEST


Providing more and sensitive data for machine learning


By focusing on new techniques for sample preparation and data analysis, as well as advances in sensors and machine learning -  we expect to enable new solutions in areas of public health with very high sensitivity and easy-to-use products that are efficient and lower cost. 


Success for us looks like ..

  • Growing revenue and margin in our targeted areas, along with increased government contracts and awards to further our scientific foundations
  • Having robust and profitable partnerships in 3-4 market segments that utilize our technologies in different ways




THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.


Bold (⌘B)

ABOUT

HEADQUARTERS
7080 N CATHEDRAL ROCK PL
Tucson, AZ 85718
VALUATION
$18.02M
PREVIOUSLY CROWDFUNDED
$744k

At Lightsense, we use optics, along with machine learning and analysis to provide better solutions for critical areas of public health like food safety, the overuse of antibiotics, and the opioid crisis. That’s why we developed a revolutionary new multispectral technology platform to redefine spectroscopy - providing a new generation of spectroscopic tools for analyzing materials and biological systems. Our company is pre-revenue and in prototyping stages with multiple patents and partnership paths underway.

TEAM

Bruce Berkoff

Bruce Berkoff

CHIEF MARKETING OFFICER

Bruce has a long history and wealth of global experience in the technology industry, having held key marketing (CMO) positions at several leading technology companies. Bruce is currently an Advisor/Mentor at SkyDeck Berkeley, EIR at Vonzos Partners, Chairman of the LCD TV Association, and a frequent advisor to various startups. He was also CMO at CBRITE, CMO/CSO at Applied Materials (AMA T)/AKT, and EVP CMO at LG Philips LCD, and others. Bruce holds undergraduate and graduate degrees in Physics and Biophysics from Princeton and UC Berkeley, respectively. He has been on the BoD of 5 public companies, including LG Display.

Wade Poteet, Ph.D.

Wade Poteet, Ph.D.

CHIEF TECHNOLOGY OFFICER

With more than 30 years experience as a research physicist/engineer, Wade has emphasized system design and manufacturing of advanced instrumentation in optics, electro-optics, and detector technology from X-rays to the far infrared spectrum, including ultra-high precision devices and large telescopes. He has received recognition awards from NASA and has a B.S. and Ph.D. in Physics from the Virginia Polytechnic Institute.

John Coates, Ph.D.

John Coates, Ph.D.

VP Optical Design

John is a veteran of the optics and spectroscopy industry with a storied career, including at Perkin-Elmer & Nicolet, with over 30 years of experience in optical spectroscopy, instrumentation & sensor design. John has been responsible for developing over 90 spectroscopy systems with a focus on miniaturization and has made key contributions to the Lightsense spectrometer products.

Richard Kris Ph.D

Richard Kris Ph.D

VP Biotechnology

Rick oversees application to non-invasive biomedical diagnostics and is coordinating collaborative work with academic research laboratories. Rick studied virology, concentrating on Influenza virus infection and has a long career (over 30 years) in diagnostics and biomedical technology, having served on the faculty of NYU School of Medicine before joining the biotech industry, first as a senior scientist at Selectide, a drug discovery company, before becoming a founder/partner in Nuvogen Research, a successful drug discovery startup. 

Joshua Nelson

Joshua Nelson

VP Finance

Josh provides financial and organizational leadership in Lightsense, including ongoing financial management, financial & tax strategy, and risk management strategy. He plays a key role in organizing the manufacturing supply chain for Lightsense spectrometers. Previously, he has provided financial leadership for multinationals (Mettler-Toledo Process Analytics) and Tucson-based startups (Sion Power Corporation, Instant Bioscan). Josh has a B.S. in Business Administration from the University of Arizona.

Kevin Harris

Kevin Harris

VP Engineering

Kevin has over 20 years of experience, including managing large programs in engineering design of optical systems and instruments, including extensive work on telescopes and space optical platforms. Kevin has extensive experience in writing software using all major protocols of electronic communication. Earlier in his career, Kevin was a Sr. Electronics and Electrical Engineer at the University of Arizona Optical Sciences. Kevin is responsible for the electronic design and data acquisition and control.

Michael Berman

Michael Berman

VP Manufacturing

Mike has 30 years' experience in microchip and MEMS development and manufacturing in the US and Asia, covering chip design, process and equipment engineering, maintenance, and production. Mike has been responsible for engineering and R&D at Advanced Micro Devices, LSI Logic and Sematech, and has over 50 patents in chip processing technology. He has played leadership roles in building manufacturing plants from Texas to Malaysia. Mike oversees manufacturing of the current Lightsense drug detection products and the manufacturing supply chain.

Michael Stanley

Michael Stanley

VP Machine Learning

Mike oversees the critically important machine learning and cloud database design, a core element in the Lightsense spectroscopy system design. His career spans three decades at Motorola Semiconductor, Freescale Semiconductor, and NXP Semiconductor, where he led efforts in machine learning development for the Sensor Division. He is a Senior Member of the IEEE, a contributor to the IEEE Standard for Sensor Performance Parameter Definitions (IEEE Std 2700TM-2014) as well as the 2nd edition of the Measurements, Instrumentation, and Sensors Handbook by CRC Press. He was inducted into the MEMS & Sensors Industry Group Hall of Fame in 2015 and he is an active member of the Industry Advisory Board for the NSF-funded Sensor, Signal, and Information Processing Center (SenSlP) at Arizona State University.

Gordon Davidson

Gordon Davidson

VP Government Programs

Gordon is overseeing Lightsense activities directed at the federal government. Gordon comes from a long and successful career in Federal Government agencies. Gordon was a Director at EPA and advisor to DOE under Clinton and has subsequently been advising a number of early stage companies, with a focus on energy and environment. Gordon is a graduate of Duke University.

Stephen Whalley

Stephen Whalley

Board Director

Steve’s career includes 25 years with Intel Corporation in pan-European and US functions directing multiple product and technology development programs. He has led and served on multiple industry association boards in the semiconductor and MEMS/sensors arenas impacting numerous successful technology developments such as USB, PCI and others.

Terje Skotheim, Ph.D.

Terje Skotheim, Ph.D.

CHIEF EXECUTIVE OFFICER

Terje is a world-renowned scientist in physics and materials science. For more than 25 years, after a successful academic career, Terje has focused on bringing technologies from the laboratory to the product stage, including advanced MEMS technology, spectrometers & sensors, lithium batteries, biosensors, and high-power lasers. Terje is part of 70 patents, 5 patent applications, and more than 200 publications. He is a founder of several start-up companies. He holds a B.S. in Physics from MIT and a Ph.D. in Physics from UC Berkeley.

TERMS

Lightsense Technology
Overview
PRICE PER SHARE
$8.57
DEADLINE
Oct 12, 2022
VALUATION
$18.02M
AMOUNT RAISED
$180,362.27
Breakdown
MIN INVESTMENT
$351.37
MAX INVESTMENT
$2,000,006.61
MIN NUMBER OF SHARES OFFERED
1,167
OFFERING TYPE
Equity
ASSET TYPE
PREFERRED
SHARES OFFERED
Series Seed Preferred Stock
MAX NUMBER OF SHARES OFFERED
233,373

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Lightsense Technology, Inc.

Corporate Address

:

7080 N CATHEDRAL ROCK PL, Tucson, AZ 85718

Offering Minimum

:

$10,001.19

Offering Maximum

:

$2,000,006.61

Minimum Investment Amount

(per investor)

:

$351.37











Terms


Offering Type

:

Equity

Security Name

:

Series Seed Preferred Stock

Minimum Number of Shares Offered

:

1,166

Maximum Number of Shares Offered

:

233,373

Price per Share

:

$8.57

Pre-Money Valuation

:

$18,018,125.05











*Maximum number of shares offered subject to adjustment for Bonus Shares. See Bonus Share info below.


Company Perks*


Audience-Based:

5% Bonus Shares for previous investors.

 

Time-Based:

Friends and Family Early Birds

Invest within the first 96 hours and receive 10% Bonus Shares.

Early Bird Bonus

Invest after the first 96 hours but within the first two weeks and receive 5% Bonus Shares.

 

Amount-Based (not "stacked" with time-based):

$1,000+

Invest $1,000+ and receive 2% Bonus Shares.

$5,000+

Invest $5,000+ and receive 5% Bonus Shares.

*All perks occur when the offering is completed.


The 10% StartEngine Owners' Bonus


Lightsense Technology will offer 10% additional Bonus Shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. Owner's bonus.


This means eligible StartEngine shareholders will receive a 10% Bonus Shares for any shares they purchase in this offering. For illustration, if an eligible StartEngine investor buys 100 shares of Series Seed Preferred Stock at $8.57 / share, that investor will receive 110 shares of Series Seed Preferred Stock, for an aggregate purchase price of $857. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.


This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.


Subject to the provision related to the Owner's Bonus in the sentence following, Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Previous Investors' Bonus in addition to the aforementioned bonus.

As provided in the Company’s Restated Certificate of Incorporation, attached as Exhibit F, the issuance of Bonus shares to an investor will lower the per-share price of all such shares issued to such investor to reflect the issuance of such additional Bonus Shares (i.e., the Bonus Shares will have the same (lower) per-share price as all other shares being purchased, determined by dividing the total purchase price paid by the investor by the total number of shares acquired (including any Bonus Shares)—for illustration, if an investor purchases 100 shares for an aggregate investment of $875 and receives 10% Bonus Shares (resulting in 110 total shares), the per-share price (“Original Issue Price”) of each share issued to such investor (including each Bonus Share) will be deemed to be $7.7009 per share).

PRESS

Article Image
Food and Beverage Technology Review

Lightsense Technology - A game changer in pathogen detection










ALL UPDATES

10.11.22

Final Hours Left to Invest!

Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, 11:59 pm, in less than 13 hours

Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!

Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:

https://www.startengine.com/lightsense-technology

10.10.22

Severn Safety Supply and Lightsense Technology team up for 2022’s International Association of Chiefs of Police (IACP) Conference being held in Dallas, Texas

October 10, 2022 – Tucson, AZ – Lightsense Technology, a pioneer of multi-spectroscopic solutions to address large problems in public health — from the opioid crisis to the pandemic, food safety and quality assurance in various supply chains — and Severn Safety Supply, a trusted supplier to Law Enforcement Organizations (LEOs) across the USA, are attending the IACP conference being held in Dallas, Texas, October 15th-18th.  The companies have formed a strategic partnership to help bring the newly launched DrugDetect-F1 to more markets in specific areas of North America.

“We at Severn Safety Supply are very excited to be a part of this conference and to have the opportunity to meet with leaders in law enforcement from around the globe!  We are looking forward to the opportunity to demonstrate the highly effective and technologically advanced DrugDetect-F1 product to these leaders.  We believe the DrugDetect-F1 will significantly increase safety for their officers by minimizing the insidious danger posed by fentanyl and methamphetamine exposure.  DrugDetech-F1’s detection technology marks an important transition to a more safe and effective drug detection method.  The technology behind DrugDetect-F1’s contactless, ‘point and click’ method of testing is truly remarkable.  Also exciting is the fact that these tests can be completed quickly, safely and efficiently, even when the product is contained in thin transparent packaging,” Commented Jeff Hall, President of Severn Safety Supply. 

“We are thrilled to partner with the experienced Severn Safety team. This show will help us both gain exposure in the handheld detector market while reaching more law enforcement organizations with our unique new tools to help with our country’s growing fentanyl problem,” remarked Bruce Berkoff, CMO of Lightsense Technology. “The DrugDetect-F1 serves as compelling evidence of the power of our new spectroscopic detection technologies, which should make law officers safer and more efficient, while helping to save lives and money. 

 

About Lightsense Technology

Lightsense has developed groundbreaking multi-spectral technology platforms, such as the patented “Enhanced Photodetection Spectroscopy” (EPS), a radical new spectroscopy architecture, for chemical, molecular and pathogen identification. Their advanced high-sensitivity mini-spectrometer designs also enable new lightweight and inexpensive handheld devices to address large vertical markets in “public health”, such as detection of illicit drugs, rapid screening for viral/bacterial pathogens, and monitoring bacterial pathogens in the food supply chain. All products are Designed, Made, & Calibrated in the USA

 

INVEST in a better future for all, see our new campaign page for our SEED round with  StartEngine, at, https://www.startengine.com/lightsense-technology

10.10.22

IACP Trade Show Banners have arrived! Invest Now in Lightsense Technology!

We are excited to share with you one of our banners for our upcoming demo at the IACP trade show happening October 16-18 in Dallas Texas. With a focus on our recent launch of the DrugDetct-F1 (handheld point-of-use fentanyl detector). This show will be foundational for us in generating sales with many police and police agencies from around the US and the world and creating shareholder value. Please join us on our journey to Public Health Detection Simplified! Only 5 days left to invest.

10.09.22

2 Days Left to Invest!

Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 2 days away.

Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!

Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:

https://www.startengine.com/lightsense-technology

10.08.22

3 Days Left to Invest!

Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 3 days away.

Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!

Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:

https://www.startengine.com/lightsense-technology

10.07.22

4 Days Left to Invest!

Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 4 days away.

Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!

Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:

https://www.startengine.com/lightsense-technology

10.06.22

Lightsense Technology Announces New Manufacturing Partnership To Help with Climate Change and Grow Revenue

Lightsense Technology, a leading provider of multi-spectroscopic solutions, is announcing a new manufacturing partnership with a large international industrial company involved in making factory equipment for the high-tech global industry.

 

This partnership will allow Lightsense know-how and IP to be used to manufacture new tools to aid in factory production, helping to optimize production parameters as well as reduce greenhouse gas emissions and make more efficient use of inputs to generate more sustainable and profitable outputs. Additional details will be announced at a later date.

 

With this new partnership, Lightsense will be able to increase its revenue base and production capacity and continue its mission of improving public health, which now includes battling climate change.

 

Lightsense will be able to provide even more innovative solutions to the most pressing issues in public health facing our world today.


Invest now before our round closes in 7 days.

 

10.06.22

5 Days Left to Invest!

Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 5 days away.

Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!

Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:

https://www.startengine.com/lightsense-technology

10.05.22

6 Days Left to Invest!

Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 6 days away.

Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!

Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:

https://www.startengine.com/lightsense-technology

10.04.22

Lightsense Technology's Current Offering is Closing in Just 7 Days. Act Now!

Our crowdfunding campaign is wrapping up! We have exciting plans for the future and want you to be a part of our journey! Our campaign closes on October 11th, only 7 days away.

Pairing sophisticated optics with best-in-class machine learning and analysis, Lightsense Technology has developed solutions for critical public health sectors - including food safety, the overuse of antibiotics, and the opioid crisis!

Thank you to all of the investors who have already invested in our company! If you haven’t yet invested or want to increase your investment, you can do so until October 11th on StartEngine at this link:

https://www.startengine.com/lightsense-technology










Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Lightsense Technology.

$351.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$1,000.00

$1,000+

Invest $1,000+ and receive 2% Bonus Shares.

$5,000.00

$5,000+

Invest $5,000+ and receive 5% Bonus Shares.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDSWe want you to succeed and get the most out of your money by offering rewards and memberships!
SECUREYour info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTSInvest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.